According to Fortune Business Insights, the global genetic testing market size was USD 33.82 billion in 2024 and is projected to grow from USD 37.32 billion in 2025 to USD 76.09 billion by 2032, exhibiting a CAGR of 10.7% during the forecast period. North America dominated the genetic testing market with a market share of 41.72% in 2024.
In May 2023, Laboratory Corporation of America entered into an agreement with Jefferson Health to expand the scope and productivity of specialty laboratory testing services.
The global genetic testing market encompasses both products—including equipment and consumables—and services. These tests analyze DNA, chromosomes, or proteins to identify genetic mutations or variants. Such insights help confirm diagnoses, assess risks for inherited conditions, and guide treatment decisions.
The market is characterized by reliability, accuracy, and rapid technological change. Rising prevalence of chronic diseases, aging populations, lifestyle risks, and increasing public and clinical awareness are major demand drivers. Technological advances like next-generation sequencing (NGS), microarrays, PCR, and hybridization enhance diagnostic precision, contributing to market expansion.
Additional growth catalysts include the demand for personalized medicine, the rising popularity of direct-to-consumer (DTC) testing, and strategic initiatives by industry players.